Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that Prof. Dr. Jan Smeitink, Chief Executive Officer at Khondrion, will present at Mitocon’s 10th Italian Meeting on Mitochondrial diseases, taking place virtually on October 9-10, 2020.
The annual meeting organized by Mitocon, Italy’s leading mitochondrial disease patient association, brings together physicians, researchers and patients from around the world, providing a unique opportunity to discuss the latest research in mitochondrial disease and the current understanding around potential pathways towards diagnosis and treatment. Since the first event in 2011, it has helped to strengthen international partnerships and collaborations between the medical community and patients, enabling knowledge sharing and the progress of research in the fight against mitochondrial diseases.
Prof. Dr. Jan Smeitink, Chief Executive Officer at Khondrion, said: “Mitochondrial diseases are complex disorders and despite the significant progress that has been made in recent years, there is still a lot of work to do in bringing treatments to patients suffering from these debilitating diseases. The entire mitochondrial disease community, including patient groups, academia and the industry, need to work together if we are to succeed in our goal of combatting mitochondrial diseases.”
Prof. Smeitink will provide a progress update on sonlicromanol, Khondrion’s lead asset, on Friday October 9, 2020, in the session “Current trials and industry”, which begins at 14.30 (CEST). Sonlicromanol is currently in Phase IIb clinical development for MELAS spectrum disorders. The United States (US) Food and Drug Administration (FDA) recently granted sonlicromanol a rare pediatric disease (RPD) designation for the treatment of patients with MELAS syndrome. Sonlicromanol has already been granted Orphan Drug Designations for MELAS syndrome, MIDD and Leigh disease in Europe, and for all inherited mitochondrial respiratory chain disorders in the US.
For more information on, or to register for Mitocon’s 10th Italian Meeting on Mitochondrial Diseases visit www.mitocon.it